Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

SPF harmonization

This article was originally published in The Rose Sheet

Executive Summary

The International Sun Protection Factor (SPF) Test Method, which sets a basis for harmonized strategy for substantiating claims on sun protection products worldwide, will initially be implemented in the EU, Japan and South Africa, the European Cosmetic, Toiletry and Perfumery Association announces. The industries, represented by their respective trade associations and joined by the U.S., signed the agreement June 1. More countries are expected to join the agreement, Colipa notes. In the U.S., FDA prescribes a method that differs "slightly," but the U.S. industry "supports and promotes the international method as the appropriate standard that all regulatory frameworks should move towards," Colipa adds. The industries of the four countries also will promote the test method as a standard of the International Standards Organization. In light of the agreement, "consumers can be assured that the same high-quality testing standard has been applied regardless of the country where they buy the products and authorities will have a tool to control the substantiation of SPF claims made by companies," Colipa adds...

You may also be interested in...



Chinese Firms Up Their Game In Novel Flu Antiviral Development

Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.

Quotable: Words Of Wisdom From Our Recent APAC Coverage

Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.

Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification

Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS014035

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel